New drug WTX-330 tested in patients with advanced cancers

NCT ID NCT05678998

First seen Jan 09, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This early-phase study tested a new drug called WTX-330 in 25 adults with advanced solid tumors or lymphoma that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study is now complete, and results will help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

  • Facility Name: Roswell Park Comprehensive Cancer Care

    Buffalo, New York, 14203, United States

  • HonorHealth

    Scottsdale, Arizona, 85258, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Mass General Hospital

    Boston, Massachusetts, 02114, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon, 97213, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.